Gem+PPIX treatment mildly delayed tumor growth and extended survival while Gem+Cel treatment was futile (Fig. 6b–d; Supplementary Fig. S11a), mirroring a failed phase II clinical trial of Gem+Cel in late-stage PDAC42. Here, GEM is linked to neoplasm.